SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending due to a significant stock drop following mixed results from a Phase 3 trial for their skin disease drug, sonelokimab. The community is actively discussing whether the sell-off is an overreaction, with some citing the company's strong cash position and potential for a buyout, while others focus on the trial's shortcomings and competitive landscape. Traders are weighing potential bounce opportunities against the risk of further decline in this volatile biotech stock.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a community-driven token focused on culture, freedom, and growth within the cannabis space. The community emphasizes positivity and connection through the Weedcoin movement, highlighting its aim to bridge culture and currency. Discussions also reference potential catalysts for the cannabis sector, further fueling interest in Weedcoin.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Dogwood Therapeutics Inc.

Dogwood Therapeutics is trending due to a recent licensing agreement for a cancer-related pain treatment, sparking community excitement.  Traders are highlighting its low float and potential for a significant upward move, drawing comparisons to other stocks with similar setups. Optimism surrounds upcoming catalysts and the possibility of a substantial price increase.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Carnival Corp is trending as it reported adjusted EPS and revenue exceeding consensus estimates, along with raising its FY25 adjusted EPS view. Community members are discussing the surprisingly strong numbers and potential for further gains, while others are wary of typical post-earnings fades. The positive results offer optimism in the cruise line sector's continued recovery.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB Construction Holdings (JFB) is trending due to a recently announced $44 million private placement, sparking discussions around the company's financial future. While some believe the funding will strengthen the company and potentially drive the stock price higher due to its low float, others are concerned about potential dilution. The community is closely watching the stock's price action and key levels amidst high trading volume.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to concerns about increased competition from a potential merger between Paramount Skydance and Warner Bros. Discovery, impacting its position in the streaming market. Community members are weighing the potential effects on content and market share, while also considering Netflix's upcoming live sports events like the Canelo fight as a possible catalyst for subscriber growth and revenue diversification through advertising.

Electronic Arts, Inc. engages in the development, marketing, publication, and distribution of games, content, and services for game consoles, PCs, mobile phones, and tablets. The company develops and publishes games and services across various genres, such as sports, first-person shooter, action, role-playing, and simulation primarily under the Battlefield, The Sims, Apex Legends, Anthem, Need for Speed, and Plants v. Zombies brands, and license games, including FIFA, Madden NFL, and Star Wars brands. The firm also provides advertising services and licenses its games to third parties to distribute and host its games. It markets and sells its games and services through digital distribution channels, as well as through retail channels, such as mass-market retailers, electronics specialty stores, and game software specialty stores. The company was founded by William M. Hawkins III and William Gordon in 1982 and is headquartered in Redwood City, CA.

Electronic Arts, Inc.

Electronic Arts is trending amid reports of a potential $50 billion buyout, which could be the largest leveraged buyout in history, with shareholders possibly receiving $210 per share. The gaming community is discussing the implications of a private equity firm and Saudi Arabia's Public Investment Fund acquiring the company, including potential changes to game development and content. Some traders are taking profits at the current level, while others anticipate further upside as the stock price has not yet reached the rumored buyout price.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending amid discussions about its strength as a safe-haven asset and potential for further gains, with some community members citing dollar weakness and central bank activity as bullish catalysts. Some traders believe GLD is overbought and due for a correction, while others remain confident in its upward trajectory, particularly in light of economic uncertainty and potential rate cuts. Community members are actively debating entry and exit points, with a few expressing concerns about a possible bubble.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending due to positive Phase 3 trial results for its oral Wegovy weight-loss pill, potentially shifting the market from injections to a more accessible daily pill; the community is weighing its potential against competitors. While some analysts are bullish, others point to layoffs and competitive pressures from Eli Lilly as reasons for concern. Community members also discuss the stock's undervaluation relative to competitors and the potential impact of market manipulation.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

GTBIF is trending as cannabis stocks react to potential rescheduling catalysts, fueled by endorsements and discussions within the community. Community members are weighing the potential benefits of rescheduling, such as tax relief and advantages over Canadian companies, while others express skepticism, citing political hurdles and past disappointments. Some investors highlight GTBIF's strong financials and potential for growth, while emphasizing the importance of value investing in the cannabis sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dogwood Therapeutics, Inc. (DWTX) shares surged 50% in the pre-market session on Monday after the company announced that it has secured a license to develop Serpin Pharma’s intravenous formulation of SP16 to manage cancer-related pain (CRP).The royalty-free, global license will enable the company to develop SP16 for a broad range of chemotherapy-induced neuropathy symptoms as well.In return, Sepin Pharma and its designated affiliates will get 7.31% of the company’s common stock, on a fully diluted basis. This includes 382,034 shares of DWTX common stock and 179.1878 shares of a new series of non-voting convertible preferred stock, it said.Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/dogwood-therapeutics-stock-soars-pre-market-on-securing-license-for-cancer-related-pain-management-drug/chDubC3R3J2">directly on Stocktwits.</a>

Rising stock market chart on a trading board background.

Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug 

In return for the license, Sepin Pharma and its designated affiliates will get 7.31% of Dogwood’s common stock, on a fully diluted basis.

Equity

In return for the license, Sepin Pharma and its designated affiliates will get 7.31% of Dogwood’s common stock, on a fully diluted basis.


Shares of Dogwood Therapeutics Inc. rose over 18% in premarket trading Friday, following a jaw-dropping 370% surge in the previous session.&nbsp;Trading volume was over 62 times the daily average, with retail investors on Stocktwits making it the most discussed biotech stock before the bell.While there was no fresh news on Friday, the rally appears to stem from an&nbsp;earlier announcement.&nbsp;Dogwood disclosed on Tuesday that it plans to begin dosing the first patient in its Phase 2b HALT-CINP trial in the first quarter of 2025.&nbsp;The trial evaluates Halneuron, a non-opioid therapy aimed at alleviating neuropathic pain linked to chemotherapy.The company’s focus on pain and fatigue-related disorders has generated excitement, bolstered by its non-opioid analgesic and antiviral platforms.&nbsp;Retail attention on Stocktwits has skyrocketed. The stock saw an 8,500% jump in message volume on Thursday, with&nbsp;its retail&nbsp;following increasing by 18% in a single day.&nbsp;<stembedurl>https://stocktwits.com/OFFC18/message/601301523</stembedurl><stembedurl>https://stocktwits.com/BullsEye2000/message/601306713</stembedurl>Dogwood stock is up over 400% year-to-date and has lost 95% over the past 12 months.&nbsp;The massive surge has reignited attention, although its low liquidity and early-stage pipeline make it a volatile bet.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% Surge

The company’s focus on pain and fatigue-related disorders has generated excitement, bolstered by its non-opioid analgesic and antiviral platforms.

https://files.quartr.com/streams/2025-09-29/18115771-d17a-4c93-b0ca-7a2339aab49d/0/live_transcript.jsonl?ref=U3RvY2t0d2l0cw==

Study Update

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Stocktwits

Stocktwits Polls

Dogwood Therapeutics is trending as traders discuss its recent exclusive worldwide license for a cancer pain treatment, with many highlighting its low float and potential for a short squeeze. The community is actively speculating on price targets and anticipating further volatility, focusing on potential breakout levels. Some traders cite upcoming catalysts, including Fibromyalgia/partnership news late in Q4.

DWTX
Dogwood Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DWTX News

DWTX Dogwood Therapeutics Inc.